Compare Citius Pharmaceuticals Inc (CTXR) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Wix.Com Ltd trades at $66.09 (market cap $2.79B). The key difference: Wix.Com Ltd is far larger — about 139.4× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | WIX | |
|---|---|---|
Market Cap | $20.01M | $2.79B |
Sector | Health | Technology |
52-Week High | $1.82 | $184.24 |
52-Week Low | $0.48 | $40.43 |
Enterprise Value | $16.23M | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Wix trades at $62.43, up 3.7% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in three of the last four quarters, while revenue grew to $1.99B in 2025. The stock faces headwinds from a class action lawsuit following a Q1 2026 miss and a 27% price drop in May 2026.
The outlook is cautiously optimistic given Wall Street's $79.75 price target and 66% buy ratings, but litigation over financial disclosures and negative shareholder equity pose significant risks. Revenue growth remains a key catalyst, though profitability volatility requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
